New cancer drug TQB3002 enters first human tests
NCT ID NCT06662760
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 16 times
Summary
This early-stage study tests a new drug, TQB3002, in 150 adults with advanced cancers that have not responded to standard treatments. The main goals are to find the safest dose and check for side effects. Researchers will also measure how the drug moves through the body. This is a first step to see if the drug might help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center
NOT_YET_RECRUITINGShenzhen, Guangdong, 518117, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Guangdong Provincial People's Hospital
RECRUITINGGuangzhou, Guangdong, 510180, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Henan Cancer Hospital
NOT_YET_RECRUITINGZhengzhou, Henan, 450003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Jiangsu Province Hospital
NOT_YET_RECRUITINGNanjing, Jiangsu, 210029, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mianyang Central Hospital
NOT_YET_RECRUITINGMianyang, Sichuan, 621099, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanghai Pulmonary Hospital
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, 200000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sichuan Cancer Hospital
NOT_YET_RECRUITINGChengdu, Sichuan, 610040, China
Contact Phone: •••-•••-••••
-
The First Affiliated Hospital Of Nanchang University
NOT_YET_RECRUITINGNanchang, Jiangxi, 330038, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Xi'an Jiao Tong University
NOT_YET_RECRUITINGXi’an, Shanxi, 710061, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Second Affiliated Hospital of Xi'an Jiaotong University
NOT_YET_RECRUITINGXi’an, Shanxi, 710004, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Yunnan Cancer Hospital
NOT_YET_RECRUITINGKunming, Yunnan, 650118, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.